Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Moderate Buy” from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has received an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $19.5556.

Several research analysts have recently weighed in on AMLX shares. Wall Street Zen upgraded Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Bank of America lifted their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 target price for the company. Finally, HC Wainwright raised their target price on Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th.

Amylyx Pharmaceuticals Trading Down 2.7%

NASDAQ:AMLX opened at $13.99 on Monday. The company has a market cap of $1.55 billion, a P/E ratio of -9.03 and a beta of -0.31. Amylyx Pharmaceuticals has a twelve month low of $3.11 and a twelve month high of $17.49. The company’s 50-day moving average price is $14.20 and its 200-day moving average price is $13.48.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01. On average, analysts expect that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Insider Activity

In other news, CEO Joshua B. Cohen sold 1,974 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $13.83, for a total value of $27,300.42. Following the completion of the sale, the chief executive officer owned 3,379,465 shares of the company’s stock, valued at $46,738,000.95. This represents a 0.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Justin B. Klee sold 1,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the sale, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. This represents a 0.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 151,203 shares of company stock worth $2,028,385. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter worth $25,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $48,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Amylyx Pharmaceuticals by 954.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after purchasing an additional 3,493 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $28,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amylyx Pharmaceuticals by 54.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after purchasing an additional 1,890 shares during the period. 95.84% of the stock is currently owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.